Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations
Current approval of the once-daily tablet indicated for patients who have undergone complete tumor removal
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.